Sarah Patterson がリツイート
I remember a long-ago @FDAOncology meeting with a small company developing an MDS drug. The company was convinced their drug was synergistic with HMAs & kept saying “we’re 2+2=5.” Finally an FDA official said they were perfectly happy for 2+2 to equal 4, if 4 was safe patients.
Anthony Letai MD PhD@DrTonyLetai
This is a VERY important message we all need to take to heart as we are designing combination therapies. Is synergy really a priority? Great job, Adam, asking the questions that need to be asked.
English
